PTC Therapeutics PTCT EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from PTC Therapeutics’s reported figures.
The official record: PTC Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about PTC Therapeutics's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is PTC Therapeutics's EBITDA?
- PTC Therapeutics (PTCT) reported EBITDA of $60.37M in Q1 2026.
- How has PTC Therapeutics's EBITDA changed year-over-year?
- PTC Therapeutics's EBITDA decreased by 93.8% year-over-year, from $977.45M to $60.37M.
- What is the long-term trend for PTC Therapeutics's EBITDA?
- Over 4 years (2021 to 2025), PTC Therapeutics's EBITDA has grown at a 33.2% compound annual growth rate (CAGR), from -$310.31M to $977.1M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.